Anebulo Pharmaceuticals (NASDAQ:ANEB) Earns “Speculative Buy” Rating from Benchmark

Benchmark reaffirmed their speculative buy rating on shares of Anebulo Pharmaceuticals (NASDAQ:ANEB) in a research note released on Tuesday morning, Marketbeat.com reports. The firm currently has a $8.00 target price on the stock.

Anebulo Pharmaceuticals Stock Down 3.5 %

ANEB opened at $1.91 on Tuesday. Anebulo Pharmaceuticals has a twelve month low of $1.62 and a twelve month high of $3.61. The company has a 50-day moving average price of $2.01 and a 200 day moving average price of $2.33. The company has a market cap of $49.53 million, a PE ratio of -5.16 and a beta of -1.01.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.08. As a group, sell-side analysts expect that Anebulo Pharmaceuticals will post -0.48 earnings per share for the current year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.